Omesh Goyal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5433269/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatology International, 2019, 13, 353-390.	1.9	483
2	Rifaximin Improves Psychometric Performance and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy (The RIME Trial). American Journal of Gastroenterology, 2011, 106, 307-316.	0.2	203
3	Corticosteroid Plus Pentoxifylline Is Not Better than Corticosteroid Alone for Improving Survival in Severe Alcoholic Hepatitis (COPE Trial). Digestive Diseases and Sciences, 2012, 57, 1664-1671.	1.1	69
4	Lâ€ornithine Lâ€aspartate in bouts of overt hepatic encephalopathy. Hepatology, 2018, 67, 700-710.	3.6	66
5	Low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol diet in patients with diarrheaâ€predominant irritable bowel syndrome: A prospective, randomized trial. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2107-2115.	1.4	54
6	Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. Liver International, 2016, 36, 378-385.	1.9	51
7	Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Scientific Reports, 2020, 10, 21117.	1.6	39
8	Indian consensus on chronic constipation in adults: A joint position statement of the Indian Motility and Functional Diseases Association and the Indian Society of Gastroenterology. Indian Journal of Gastroenterology, 2018, 37, 526-544.	0.7	34
9	Prevalence, overlap, and risk factors for Rome IV functional gastrointestinal disorders among college students in northern India. Indian Journal of Gastroenterology, 2021, 40, 144-153.	0.7	24
10	Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet <i>versus</i> traditional dietary advice for functional dyspepsia: a randomized controlled trial. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 301-309.	1.4	24
11	Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure. Hepatology International, 2021, 15, 970-982.	1.9	23
12	New paradigms in management of alcoholic hepatitis: a review. Hepatology International, 2017, 11, 255-267.	1.9	21
13	Minimal Hepatic Encephalopathy in Cirrhosis- How Long to Treat?. Annals of Hepatology, 2017, 16, 115-122.	0.6	21
14	Clinical profile of hepatitis C virus infection in a developing country: India. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 926-933.	1.4	20
15	Early feeding after esophageal variceal band ligation in cirrhotics is safe: Randomized controlled trial. Digestive Endoscopy, 2019, 31, 646-652.	1.3	16
16	Impact of metabolic risk factors on the severity and outcome of patients with alcoholâ€associated acuteâ€onâ€chronic liver failure. Liver International, 2021, 41, 150-157.	1.9	13
17	Profile of hepatocellular carcinoma in a tertiary care hospital in Punjab in northern India. Indian Journal of Gastroenterology, 2014, 33, 35-40.	0.7	12
18	Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF. Hepatology International, 2021, 15, 753-765.	1.9	12

#	Article	IF	CITATIONS
19	Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naÃ⁻ve â€~real-life' patients in India. Indian Journal of Gastroenterology, 2014, 33, 343-349.	0.7	11

The Practice of Gastrointestinal Motility Laboratory During COVID-19 Pandemic: Position Statements of the Asian Neurogastroenterology and Motility Association (ANMA-GML-COVID-19 Position) Tj ETQq0 0 0 rgBT /Oværlock 101Tf 50 697

21	Skin and soft tissue infections in cirrhotics: A prospective analysis of clinical presentation and factors affecting outcome. Indian Journal of Gastroenterology, 2014, 33, 281-284.	0.7	10
22	Esophageal motility disorders—Symptomatic and manometric spectrum in Punjab, northern India. Indian Journal of Gastroenterology, 2017, 36, 202-208.	0.7	10
23	Clinical and anorectal manometry profile of patients with functional constipation and constipation-predominant irritable bowel syndrome. Indian Journal of Gastroenterology, 2019, 38, 211-219.	0.7	7
24	Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study. Hepatology International, 2017, 11, 277-285.	1.9	5
25	Rifaximin Improves Cognitive Functions and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial (The RIME) Tj ETQq1	1 0. 78431	.43rgBT /Ov
26	Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy. Annals of Hepatology, 2014, 13, 503-509.	0.6	2
27	HCC surveillance results in earlier HCC detection: results from an Indian cohort. SpringerPlus, 2014, 3, 610.	1.2	2
28	Genotypic Distribution and Associated Disease Pattern of Hepatitis C Virus in Northern India. Journal of Gastrointestinal Infections, 2014, 4, 40-43.	0.1	2
29	Quality of life in Indian patients with functional dyspepsia: Translation and validation of the Hindi version of Short-Form Nepean Dyspepsia Index. Indian Journal of Gastroenterology, 2022, 41, 378-388.	0.7	2
30	Leptospirosis- ls Cirrhosis a Predisposing Factor?. Gastroenterology, 2011, 140, S-460.	0.6	1
31	Response to Zullo et al American Journal of Gastroenterology, 2011, 106, 2041-2042.	0.2	1
32	Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response. Journal of Clinical and Experimental Hepatology, 2015, 5, 2-7.	0.4	1
33	Minimal Hepatic Encephalopathy in Cirrhosis: How Long to Treat? Does Minimal Hepatic Encephalopathy Relapse after Treatment?. American Journal of Gastroenterology, 2016, 111, S371.	0.2	1
34	THU-040-AARC score: A dynamic model to predict outcome in acute on chronic liver failure patients. Journal of Hepatology, 2019, 70, e177.	1.8	1
35	Treatment of Patients with Chronic Hepatitis Genotype 3 Infection with/without Cirrhosis with Sofosbuvir and Daclatasvir Therapy. Gastroenterology, 2017, 152, S1091-S1092.	0.6	1
36	Author's reply to comment on the article: Psychological issues in patients with irritable bowel syndrome: Throwing more light is necessary. Indian Journal of Gastroenterology, 2021, 40, 646-647.	0.7	1

Omesh Goyal

#	Article	IF	CITATIONS
37	Reply. Hepatology, 2018, 67, 797-798.	3.6	Ο
38	THU-045-Natural history of sepsis, organ failure and organ dysfunction in critically ill patients with acute on chronic liver failure. Journal of Hepatology, 2019, 70, e179-e180.	1.8	0
39	Genotypic Distribution and Associated Disease Pattern of Hepatitis C Virus in Northern India. Journal of Gastrointestinal Infections, 2014, 4, 40-43.	0.1	Ο
40	Spontaneous Bacterial Infections in Cirrhosis- Peritonitis and Beyond. Journal of Gastrointestinal Infections, 2014, 4, 1-3.	0.1	0
41	Spontaneous Bacterial Infections in Cirrhosis- Peritonitis and Beyond. Journal of Gastrointestinal Infections, 2014, 4, 1-3.	0.1	Ο
42	Treatment results and factors affecting sustained virological response in chronic hepatitis C patients in Northern India. Journal of Gastrointestinal Infections, 2015, 5, 24-30.	0.1	0
43	Treatment of Chronic Hepatitis with Sofosbuvir in Combination with Ribavirin with or without Pegylated Interferon. American Journal of Gastroenterology, 2016, 111, S383.	0.2	0
44	L-Ornithine L-Aspartate In Acute Overt Hepatic Encephalopathy. American Journal of Gastroenterology, 2017, 112, S546-S548.	0.2	0